Replies to post #355369 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Great point Dan88. As we know, Dr. Keyoumars was the Principal Investigator for the DCVax-L Phase III trial in the UK & the entire EU. As such, I believe he has seen the unblinded & unblended DCVax-L TLD. I believe he is also helping to write & review the DCVax-L trial results peer-reviewed journal article.

If he did not know first-hand that DCVax-L is very safe & effective for GBM patients, he would not be advocating to treat his patients with it, especially at a cost of £200,000+.

I also believe that Dr. Keyoumars is one of the experts that NWBio has consulted with regarding the path forward, including the timing of publicly releasing TLD & publishing the data in a peer-reviewed medical journal.

[trocprofit]

That is a VERY interesting point and I never put those two ideas together. Since the company is unblinded and preparing topline release, they could have huge liability if they were offering the treatment in the U.K. knowing full well it wouldn't help. So, since they continue to offer treatment, it has to be a validation of the science and efficacy. Right?